MARCHEX INC
b672021160e91d179ed162efe45aa2bf558bd0b0
MARCHEX INC entered into Settlement Agreement valued at $750,000 (and agree to the release of $250,000 held in escrow by U.S. Bank) (effective 2026-04-14).
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
ImmuCell settles Norbrook dispute, to receive $2M payment
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.
SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.
MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).
Camden Property Trust settles RealPage antitrust class action for $53M
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
On April 7, 2026, Camden Property Trust, on behalf of itself and related entities (collectively, the “Company”) entered into a binding term sheet for a settlement with the named plaintiffs in the Class Action Litigation, individually and on behalf of the class members (together, the “Plaintiffs”).
Southland subsidiary settles WA convention center lawsuit; sureties to pay additional $26.5M
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
On March 27, 2026, American Bridge Company (“American Bridge”), a wholly owned subsidiary of Southland Holdings, Inc. (the “Company”), entered into a Settlement Agreement and Release of Claims (the “Settlement Agreement”) with Clark/Lewis, a Joint Venture (“Clark/Lewis”), certain sureties of American Bridge (the “Sureties”), the Washington State Convention Center (“WSCC”), and American Bridge’s litigation counsel.
Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.
Orion settles Voltrek earnout dispute for $3M cash; solar PPA exit adds $1.3M offset
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
On March 17, 2026, Orion Energy Systems, Inc. and its subsidiaries (collectively, the “ Company ”) entered into a settlement agreement (the “ Settlement Agreement ”) with Final Frontier, LLC (“ Final Frontier ”) and Kathleen M. Connors (“ Ms. Connors ”), personally and as Trustee of the Kathleen M. Connors 2019 Revocable Trust
REGENXBIO settles GSK sublicense fee dispute for $10M
This filing
On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.
Comparable filing
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.